Notícias

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.

BridgeBio Pharma's Attruby sales are surging, but can growth keep justifying its premium valuation amid execution risks and rising costs?

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.

For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.

Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...

The S&P 500 keeps climbing, up nearly 9% year to date, and yet a handful of large-cap dividend payers are trading like the bull market forgot they exist. That is exactly where opportunity hides in July. If you have $1,000 to put to work, three NYSE-listed names stand out on valuation, cash flow, and payout ... 3 Absurdly Cheap Dividend Stocks to Buy With $1,000 in July

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer Inc. (NYSE:PFE) is one of the dividend stocks picked by financial media as investors ask whether dividend stocks are tax-efficient. On June 24, Pfizer said its board declared a $0.43 third-quarter dividend on the company’s common stock, payable September 1 to holders of record at the close of business on July 24. Pfizer also […]

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

They may not remain cheap for too much longer.

Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index. The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters. Pfizer’s high yield reflects investors’ trepidation over the stock.

Construction at Pfizer’s former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues. The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the index, at more than 7%. Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.

The former Pfizer headquarters in Midtown has continued to move since emergency responders arrived, officials said Tuesday.

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

A high-rise building in Manhattan was at risk of collapse after columns buckled and floors sagged, officials said Tuesday, prompting an emergency response during the rush-hour commute. Fire officials said they received a report that bricks were falling from the 38-story building, in the city’s midtown district just before 8 a.m. Officials determined that two columns had buckled on the building’s 21st and 22nd floors and that several floors near the columns were sagging. No injuries were reported, fire officials said.

A 7% dividend yield will grab your attention, but be sure to read the fine print.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July

Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. […]

Could this be the secret to Pfizer's rebound strategy?

(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO

The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.

Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...